Molecular Imaging Market to Expand at 10.8% CAGR Through 2032, Reveals Persistence Market Research

The global molecular imaging market is witnessing unprecedented momentum, poised to grow from a market size of US$ 6.1 billion in 2025 to an estimated US$ 16.8 billion by 2032. This surge reflects a robust CAGR of 10.8% during the forecast period from 2025 to 2032. The market growth is driven by the escalating burden of cancer, cardiovascular, and neurological disorders, coupled with an aging population and increasing focus on early and accurate disease diagnosis. The demand for precise diagnostic tools that offer real-time and functional insights into cellular activities is fueling the adoption of molecular imaging technologies.

Get a Sample PDF Brochure of the Report (Use Corporate Email ID for a Quick Response): https://www.persistencemarketresearch.com/samples/34761

Among the different market segments, SPECT (Single Photon Emission Computed Tomography) is expected to lead with a 43.3% share in 2025, thanks to its versatile applications and diagnostic accuracy. Meanwhile, the oncology segment will dominate the application front, capturing a projected 42.8% share, owing to the global rise in cancer incidence. Geographically, North America stands as the front-runner, anticipated to hold a 42% market share in 2025, supported by advanced healthcare infrastructure, strong reimbursement systems, and a high prevalence of chronic illnesses.

✦ Key Highlights from the Report:

✦ The global market is projected to grow at a CAGR of 10.8% between 2025 and 2032.
✦ Oncology application is set to dominate with a 42.8% market share by 2025.
✦ SPECT modality will lead the segment with a projected 43.3% share in 2025.
✦ North America will capture 42% of the total market share in 2025.
✦ Integration of AI and ML is enhancing diagnostic precision and efficiency.
✦ Asia Pacific region expected to grow at a CAGR of 5.54% during the forecast period.

📊 Market Segmentation

The molecular imaging market is segmented based on imaging modality, application, and end-user.

In terms of modality, the market includes Positron Emission Tomography (PET), Single Photon Emission Computed Tomography (SPECT), and molecular ultrasound imaging. SPECT is leading due to its cost-effectiveness, broad availability, and clinical utility in neurology and cardiology. Technological enhancements like improved image resolution and faster scan times have reinforced its market leadership.

From an application standpoint, oncology holds the largest share, owing to the increasing global cancer burden. The capacity of molecular imaging to provide early and precise detection, monitor treatment efficacy, and offer personalized therapy has made it indispensable in cancer diagnostics. Neurology and cardiology follow as other prominent application areas, supported by the need for accurate assessments of brain function and cardiac health.

End-users in the molecular imaging space primarily include hospitals, diagnostic imaging centers, and academic research institutions. Hospitals dominate the segment due to their comprehensive diagnostic infrastructure and ability to incorporate advanced imaging systems, followed by specialized imaging centers which cater to outpatient diagnostic needs.

Read More In Detail: https://www.persistencemarketresearch.com/market-research/molecular-imaging-market.asp

🌍 Regional Insights

North America

North America, particularly the United States, leads the global molecular imaging market with an estimated 42% value share in 2025. The region's dominance is underpinned by a high prevalence of cancer, strong adoption of technological innovations, favorable reimbursement policies, and established healthcare systems. These elements collectively ensure early diagnosis and improved patient care outcomes.

Europe

Europe is steadily advancing in the molecular imaging sector, driven by its aging population and the growing prevalence of chronic diseases. Countries like the UK and Germany are investing significantly in healthcare modernization and personalized medicine. The European market benefits from governmental support for early disease detection initiatives, which is fueling the use of PET, SPECT, and MRI technologies.

Asia Pacific

Asia Pacific is projected to register the highest growth, with a CAGR of 5.54% through 2032. Developing nations such as China, India, and Thailand are strengthening their healthcare infrastructure and increasing investments in diagnostic technologies. Rising awareness about early disease detection and expanding access to advanced imaging tools are key growth factors in this region.

🚀 Market Drivers

The global burden of chronic diseases such as cancer, cardiovascular disorders, and neurological conditions is rising sharply, pushing the need for advanced diagnostic methods. Molecular imaging fulfills this requirement by allowing visualization of molecular and cellular activity in real time. The World Health Organization reports that cardiovascular diseases alone claim 17.9 million lives annually, highlighting the urgent need for diagnostic innovation.

Furthermore, personalized medicine is becoming central to modern healthcare, increasing demand for tailored diagnostic solutions. Molecular imaging systems support precision healthcare by enabling accurate disease staging and monitoring therapeutic efficacy. Additionally, continuous R&D investments, especially in radiotracer development, are further expanding the potential applications of molecular imaging.

🛑 Market Restraints

Despite strong potential, the molecular imaging market faces significant restraints. High capital investment required for equipment like PET/CT scanners and the operational cost of radiotracers make these technologies less accessible, especially in low- and middle-income countries. Moreover, regulatory and reimbursement challenges hinder market penetration. Lengthy approval processes and inconsistent reimbursement frameworks create uncertainty for healthcare providers and manufacturers alike.

A shortage of skilled professionals also limits the widespread adoption of advanced imaging systems. Handling complex imaging technologies requires specialized training, which is not uniformly available across regions, especially in emerging markets.

💡 Market Opportunities

The integration of Artificial Intelligence (AI) and Machine Learning (ML) into molecular imaging is a game-changer. These technologies enhance image analysis, improve diagnostic accuracy, and streamline workflows. For example, GE HealthCare's LesionID Pro, launched in 2025, automates whole-body tumor quantification, reducing manual workloads and expediting diagnosis.

AI and ML are also facilitating real-time monitoring and personalized treatment planning by integrating imaging data with clinical and genomic profiles. This advancement addresses workforce shortages and elevates patient care standards. As these technologies evolve, they are set to redefine the capabilities of molecular imaging and create new revenue streams for industry players.

Do You Have Any Query Or Specific Requirement? Request Customization of Report: https://www.persistencemarketresearch.com/request-customization/34761

📌 Reasons to Buy the Report:

✔ Gain in-depth understanding of current and future market trends.
✔ Identify high-growth segments and regions to focus investments.
✔ Evaluate market opportunities driven by AI and technological advancements.
✔ Benchmark key players and understand competitive strategies.
✔ Support strategic planning with accurate market forecasts through 2032.

🏢 Company Insights

• Bruker
• GE HealthCare
• Siemens Healthineers
• Koninklijke Philips N.V.
• Canon Medical Systems Corporation
• Mediso
• Cubresa Inc.
• Shimadzu Corporation
• United Imaging Healthcare Co.
• Positron Corporation

Recent Developments

In June 2025, GE HealthCare launched advanced molecular imaging solutions at SNMMI 2025 for improved cardiac diagnostics.

In May 2025, Chalmers University established the CII Research Platform with a Bruker MRMS MALDI system for advanced imaging applications.

In January 2025, Siemens Healthineers acquired Novartis' Advanced Accelerator Applications unit, expanding its PETNET capabilities in Europe.

📚 Conclusion

The molecular imaging market is on a transformative path, backed by growing demand for early diagnosis, personalized treatment, and advanced imaging solutions. While high costs and regulatory barriers pose challenges, the integration of AI and ML and increasing investments in healthcare infrastructure present significant growth opportunities. The dominance of North America and rapid growth in Asia Pacific underline the global relevance of this market. As technology continues to evolve, molecular imaging is expected to become an even more vital component of precision medicine and modern diagnostics, positioning itself as a cornerstone of future healthcare strategies.

Persistence Market Research
G04 Golden Mile House, Clayponds Lane
Brentford, London, TW8 0GU UK
USA Phone: +1 646-878-6329
UK Phone: +44 203-837-5656
Email: sales@persistencemarketresearch.com
Web:
https://www.persistencemarketresearch.com

About Persistence Market Research:

At Persistence Market Research, we specialize in creating research studies that serve as strategic tools for driving business growth. Established as a proprietary firm in 2012, we have evolved into a registered company in England and Wales in 2023 under the name Persistence Research & Consultancy Services Ltd. With a solid foundation, we have completed over 3600 custom and syndicate market research projects, and delivered more than 2700 projects for other leading market research companies' clients.

Our approach combines traditional market research methods with modern tools to offer comprehensive research solutions. With a decade of experience, we pride ourselves on deriving actionable insights from data to help businesses stay ahead of the competition. Our client base spans multinational corporations, leading consulting firms, investment funds, and government departments. A significant portion of our sales comes from repeat clients, a testament to the value and trust we've built over the years.

This release was published on openPR.